NEW YORK (GenomeWeb News) – Accelr8 reported last week that its fiscal second-quarter revenues plummeted to $8,328 from $313,568 a year ago as a result of the expiration of an agreement with Novartis.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.